VERADERMICS ($MANE) is a biotech targeting the $9B hair loss market with a first-in-class oral, non-hormonal pill. It priced an upsized IPO at $17, raising ~$256M at a ~$606M valuation, then doubled o

The lead asset VDPHL01 is Phase 3-ready for androgenetic alopecia, a condition hitting roughly 50M men and 30M women in the U.S. A massive untreated population meets a massive commercial opportunity. Dermatologist-founded in 2019 by CEO Dr. Reid Waldman, the company is backed by top-tier VCs like Longitude Capital and SR One. Proceeds will fund the pivotal trial and prep for potential commercialization. The blowout debut signals strong post-pandemic appetite for biotech, riding a wave of early 2025 IPOs like Eikon and Braveheart. Still, a tricky macro backdrop of tariff risk and FDA uncertainty looms. Bottom line: $MANE is a classic high-risk, high-reward biotech story—binary Phase 3 outcome ahead, but a monster market and insider-led thesis are fueling early momentum.

The lead asset VDPHL01 is Phase 3-ready for androgenetic alopecia, a condition hitting roughly 50M men and 30M women in the U.S. A massive untreated population meets a massive commercial opportunity.